BioSpace News Archive

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023 at 11:40 a.m. ET / 8:40 a.m. PT.

Scinai Immunotherapeutics Ltd. announced the closing of its previously announced registered direct offering of 1,146,552 of the Company’s American Depositary Shares, each ADS representing four hundred ordinary shares, at a purchase price of $1.16 per ADS.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh Patel, President and Chief Executive Officer, will present and meet with investors at the 2023 Cantor Fitzgerald Global Healthcare Conference to take place September 26th to September 28th in New York City.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported important progress related to the regulatory pathway for tabelecleucel (tab-cel®) in the U.S.

Align Technology, Inc. shared highlights from the 2023 Invisalign GP Summit, the Company’s premier clinical education and networking experience designed to help doctors transform and grow their practice with Invisalign® clear aligners, iTero scanners, and the Align Digital Platform™.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications.

NANOBIOTIX announced that it will report its financial results for half-year ending June 30, 2023, on Tuesday, September 26, 2023, after the close of the US market.

HilleVax, Inc. announced that it intends to offer and sell, subject to market and other conditions, $100.0 million of shares of its common stock in an underwritten public offering.

SomaLogic Inc., a leader in data-driven proteomics technology, announced its partnership with DNA Link, an innovator in personalized and precision medicine, to offer the 7,000-plex SomaScan® platform to their customers.

CSL Seqirus, a business of CSL, shared new real-world evidence studies conducted in the United States, demonstrating the value of influenza vaccination in protecting public health.